Terms: = Lung cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
28 results:
1. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.
Ci M; Zhao G; Li C; Liu R; Hu X; Pan J; Shen Y; Zhang G; Li Y; Zhang L; Liang P; Cui H
Cell Death Dis; 2024 Mar; 15(3):179. PubMed ID: 38429268
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
Biswas S; Mandal G; Anadon CM; Chaurio RA; Lopez-Bailon LU; Nagy MZ; Mine JA; Hänggi K; Sprenger KB; Innamarato P; Harro CM; Powers JJ; Johnson J; Fang B; Eysha M; Nan X; Li R; Perez BA; Curiel TJ; Yu X; Rodriguez PC; Conejo-Garcia JR
Immunity; 2023 Nov; 56(11):2570-2583.e6. PubMed ID: 37909039
[TBL] [Abstract] [Full Text] [Related]
4. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
5. Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
Duffau H
J Neurooncol; 2023 Mar; 162(1):237-244. PubMed ID: 36913047
[TBL] [Abstract] [Full Text] [Related]
6. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
[TBL] [Abstract] [Full Text] [Related]
7. Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (idh1) on the Cellular Metabolome of Leukemic Cells.
Shait Mohammed MR; Alzahrani F; Hosawi S; Choudhry H; Khan MI
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743098
[TBL] [Abstract] [Full Text] [Related]
8. Molecular and clinical characteristics of idh mutations in Chinese NSCLC patients and potential treatment strategies.
Chen S; Zhu H; Jin M; Yuan H; Liu Z; Li J; Zhang X; Meng L; Li T; Diao Y; Gao H; Hong C; Zhu X; Zheng J; Li F; Niu Y; Ma T; Li X
Cancer Med; 2022 Nov; 11(22):4122-4133. PubMed ID: 35526267
[TBL] [Abstract] [Full Text] [Related]
9. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract] [Full Text] [Related]
10. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
Neumann JM; Freitag H; Hartmann JS; Niehaus K; Galanis M; Griesshammer M; Kellner U; Bednarz H
J Cancer Res Clin Oncol; 2022 Feb; 148(2):351-360. PubMed ID: 34839410
[TBL] [Abstract] [Full Text] [Related]
11. The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients.
Zhang X; Ma S; Chen Y; Yin Y; Bai W; Tan J; Shi G
Int J Biol Markers; 2021 Dec; 36(4):27-35. PubMed ID: 34761718
[TBL] [Abstract] [Full Text] [Related]
12. Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker.
Chen AX; Gartrell RD; Zhao J; Upadhyayula PS; Zhao W; Yuan J; Minns HE; Dovas A; Bruce JN; Lasorella A; Iavarone A; Canoll P; Sims PA; Rabadan R
Genome Med; 2021 May; 13(1):88. PubMed ID: 34011400
[TBL] [Abstract] [Full Text] [Related]
13. Poor prognosis of male triple-positive breast cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract] [Full Text] [Related]
14. The molecular basis of gender disparities in smoking lung cancer patients.
Davuluri S; Bajpai AK; Thirumurugan K; Acharya KK
Life Sci; 2021 Feb; 267():118927. PubMed ID: 33358908
[TBL] [Abstract] [Full Text] [Related]
15. PTEN, ATM, idh1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
Blons H; Oudart JB; Merlio JP; Debieuvre D; de Fraipont F; Audigier-Valette C; Escande F; Hominal S; Bringuier PP; Fraboulet-Moreau S; Ouafik L; Moro-Sibilot D; Lemoine A; Langlais A; Missy P; Morin F; Souquet PJ; Barlesi F; Cadranel J; Beau-Faller M;
Lung Cancer; 2021 Jan; 151():69-75. PubMed ID: 33248711
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract] [Full Text] [Related]
17. Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the lung in East Asian Patients.
Kim M; Chung YS; Kim KA; Shim HS
In Vivo; 2020; 34(6):3375-3385. PubMed ID: 33144445
[TBL] [Abstract] [Full Text] [Related]
18. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with
Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J; Leonce C; Jovelet C; Pradines A; Avrillon V; Chumbi Flores WR; Lacroix L; Loriot Y; Westeel V; Ngo-Camus M; Tissot C; Raynaud C; Gervais R; Brain E; Monnet I; Giroux Leprieur E; Caramella C; Mahier-Aït Oukhatar C; Hoog-Labouret N; de Kievit F; Howarth K; Morris C; Green E; Friboulet L; Chabaud S; Guichou JF; Perol M; Besse B; Blay JY; Saintigny P; Planchard D
Clin Cancer Res; 2020 Dec; 26(23):6242-6253. PubMed ID: 32859654
[TBL] [Abstract] [Full Text] [Related]
19. Overcoming Resistance to Targeted Therapies in Gastrointestinal cancers: Progress to Date and Progress to Come.
Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
[TBL] [Abstract] [Full Text] [Related]
20. High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
Baldacci S; Figeac M; Antoine M; Descarpentries C; Kherrouche Z; Jamme P; Copin MC; Tulasne D; Nanni I; Beau-Faller M; Melaabi S; Levallet G; Quoix E; Moro-Sibilot D; Friard S; Missy P; Barlesi F; Cadranel J; Cortot AB
J Thorac Oncol; 2020 Jan; 15(1):120-124. PubMed ID: 31605799
[TBL] [Abstract] [Full Text] [Related]
[Next]
